Join us for a complimentary CME/CE Live Virtual Symposium during ICS 2020 Online

Improving Outcomes in OAB: Emerging Strategies to Reduce Symptom Burden and Treatment Adverse Effects

Friday, November 20, 2020
15:00 - 16:00 GMT/ 10:00 am – 11:00 am ET/ 07:00 am – 08:00 am PT

Faculty

Roger Dmochowski, MD, MMHC, FACS (Chair)
Associate Surgeon in Chief
Professor of Urology
Professor of Obstetrics and Gynecology
Vice Chair, Section of Surgical Sciences
Vanderbilt University Medical Center
Nashville, Tennessee

Benjamin M. Brucker, MD
Associate Professor, NYU Langone Medical Center
Department of Urology and Obstetrics and Gynecology
Director of FPMRS and Neurourology
NYU Langone
New York, New York

Activity Description

Overactive bladder (OAB) is a common condition that can significantly impair quality of life and carries a substantial personal and societal economic burden. Available evidence indicates that OAB is undertreated and inappropriately treated through the use if antimuscarinic medications in patients with dementia. Current and emerging β3-adrenoceptor agonist therapies may have a better risk:benefit profile. The desired results of this activity are for urologists and other clinicians to improve their diagnosis and treatment of OAB.

Target Audience

This activity intends to educate urologists, urogynecologists, physician assistants, nurse practitioners, nurses, and other clinicians caring for patients with overactive bladder.

Learning Objectives

After completing this activity, participants will be better able to:

• Apply efficacy and tolerability clinical data to develop long-term treatment plans for patients with overactive bladder
• Incorporate medication reviews into patient encounters
• Compare the data on central nervous system effects of antimuscarinic overactive bladder medications with those of β3-adrenoceptor agonists
• Describe the pharmacologic, efficacy, safety, and tolerability profile of emerging treatment for overactive bladder

For Physicians:

ACCME Accreditation Statement
MedEdicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit Designation Statement

MedEdicus designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

Instructions for Obtaining Credit

To obtain credit for this activity, please view the virtual symposium and proceed via the link to complete the post-assessment and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.

Provider Contact

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Disclosure of Unlabeled Use

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Urovant Sciences.

This activity is provided by MedEdicus LLC.

This continuing medical education activity is supported through an unrestricted educational grant from Urovant Sciences.

The views expressed in this Satellite Symposium are those of the company and speakers and not necessarily those of the International Continence Society.